REPICE, ANNA MARIA RITA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.578
EU - Europa 4.267
AS - Asia 2.888
SA - Sud America 309
Continente sconosciuto - Info sul continente non disponibili 150
AF - Africa 128
OC - Oceania 28
Totale 13.348
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.467
RU - Federazione Russa 1.559
IT - Italia 908
SG - Singapore 749
CN - Cina 727
PL - Polonia 585
HK - Hong Kong 426
IE - Irlanda 330
VN - Vietnam 276
BR - Brasile 247
SE - Svezia 235
KR - Corea 215
DE - Germania 153
FR - Francia 133
FI - Finlandia 115
IN - India 112
JO - Giordania 95
GB - Regno Unito 77
CA - Canada 71
JP - Giappone 63
BD - Bangladesh 38
CH - Svizzera 31
NL - Olanda 30
MA - Marocco 29
UA - Ucraina 29
ID - Indonesia 27
AU - Australia 26
SA - Arabia Saudita 26
TR - Turchia 26
ES - Italia 25
CI - Costa d'Avorio 24
IR - Iran 22
MX - Messico 22
AR - Argentina 20
NG - Nigeria 20
ZA - Sudafrica 20
IQ - Iraq 18
EC - Ecuador 15
EG - Egitto 14
CO - Colombia 10
PH - Filippine 10
PK - Pakistan 10
BE - Belgio 8
CZ - Repubblica Ceca 8
KE - Kenya 8
LT - Lituania 7
UZ - Uzbekistan 7
NP - Nepal 6
CL - Cile 5
MY - Malesia 5
AT - Austria 4
DZ - Algeria 4
HN - Honduras 4
IL - Israele 4
PT - Portogallo 4
UY - Uruguay 4
AZ - Azerbaigian 3
BJ - Benin 3
DK - Danimarca 3
GT - Guatemala 3
LV - Lettonia 3
SK - Slovacchia (Repubblica Slovacca) 3
TH - Thailandia 3
VE - Venezuela 3
AL - Albania 2
BH - Bahrain 2
BO - Bolivia 2
BY - Bielorussia 2
ET - Etiopia 2
HU - Ungheria 2
JM - Giamaica 2
KG - Kirghizistan 2
LI - Liechtenstein 2
LK - Sri Lanka 2
MQ - Martinica 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PE - Perù 2
PS - Palestinian Territory 2
SI - Slovenia 2
TN - Tunisia 2
AE - Emirati Arabi Uniti 1
BG - Bulgaria 1
CG - Congo 1
CR - Costa Rica 1
CY - Cipro 1
DO - Repubblica Dominicana 1
GD - Grenada 1
IS - Islanda 1
KH - Cambogia 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LC - Santa Lucia 1
LU - Lussemburgo 1
MM - Myanmar 1
NI - Nicaragua 1
OM - Oman 1
PA - Panama 1
Totale 13.190
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.423
Ashburn 753
Warsaw 578
Singapore 533
Hong Kong 375
Dublin 330
Chandler 284
Fairfield 275
San Jose 240
Milan 219
Seoul 215
Beijing 201
Hefei 118
Lawrence 107
Los Angeles 107
Altamura 101
Woodbridge 101
Seattle 100
Buffalo 98
Ho Chi Minh City 98
Houston 92
Rome 91
Florence 86
Munich 84
Cambridge 77
Princeton 72
Wilmington 72
Lauterbourg 68
Kent 63
Tokyo 63
Ann Arbor 61
Mumbai 61
New York 61
Boston 60
Hanoi 58
Council Bluffs 55
The Dalles 53
Moscow 50
Turku 50
Clifton 43
Dallas 41
Shanghai 39
Dearborn 37
Helsinki 36
Paris 35
Jacksonville 30
São Paulo 28
Bern 27
San Diego 25
Abidjan 24
Frankfurt am Main 24
Orem 24
Medford 23
Casablanca 22
Riyadh 22
Boardman 21
Jakarta 21
Melbourne 20
Abuja 19
Lappeenranta 18
Chennai 17
Bologna 16
Toronto 16
Brooklyn 15
Da Nang 15
London 15
Naples 15
Norwalk 15
Palermo 15
Amman 14
Montreal 14
Chicago 13
Guangzhou 13
Redondo Beach 13
Barcelona 12
Amsterdam 11
Falls Church 11
Johannesburg 11
Turin 11
Yubileyny 11
Istanbul 10
Manchester 10
Phoenix 10
Stockholm 10
Atlanta 9
Cairo 9
Denver 9
Poplar 9
Belo Horizonte 8
Bengaluru 8
Dong Ket 8
Haiphong 8
Modena 8
Rio de Janeiro 8
Basingstoke 7
Biên Hòa 7
Bremen 7
Catania 7
Tianjin 7
Venice 7
Totale 8.551
Salva come PNG Salva come JPEG
Nome #
Markers of JC virus infection in patients with multiple sclerosis under natalizumab therapy. 334
Central vein sign differentiates MS from CNS inflammatory vasculopathies. 321
Azathioprine versus Beta Interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial. 307
No proinflammatory signature in CD34+ hematopoietic progenitor cells in multiple sclerosis patients. 299
Disease reactivation following fingolimod withdrawal in multiple sclerosis: Two case reports. 230
The TCR Repertoire Reconstitution in Multiple Sclerosis: Comparing One-Shot and Continuous Immunosuppressive Therapies 223
MRI analysis of the "central vein sign" allows identification of a subset of relapsing remitting MS patients with brain pathology different from inflammatory demyelination 217
Safety and efficacy of autologous hematopoietic stem cell transplantation following natalizumab discontinuation in aggressive Multiple Sclerosis 216
Spinal cord size as promising biomarker of disability outcomes after hematopoietic stem cell transplantation in multiple sclerosis 202
Clinical characteristics predicting relapses following disease modifying therapies discontinuation in multiple sclerosis: a monocentric cohort study 202
Effect of the COVID-19 pandemic on disease activity in multiple sclerosis patients treated with hematopoietic stem cell transplantation 201
Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: The Italian multi-centre experience 200
Immunohistochemistry analysis of bone marrow biopsies in multiple sclerosis patients undergoing autologous haematopoietic stem cells transplantation 196
Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: A monocentric experience 194
Accuracy of the central vein sign evaluation by brain MRI for the pathologic characterization of multiple sclerosis cases with markers of "better explanation" of the diagnosis. 194
Clinical and paraclinical findings in a case series of MOGAD: Exploring the presence of perivenular brain white matter lesions 189
Effect of disease-modifying treatments on antibody-mediated response to anti- COVID19 vaccination in people with multiple sclerosis 189
Efficacy of Azathioprine on Multiple Sclerosis new brain lesions evaluated using Magnetic Resonance Imaging. 187
Neuropsychological assessment in aggressive multiple sclerosis treated with stem cell transplantation 183
A whole genome screen for linkage disequilibrium in multiple sclerosis performed in a continental Italian population. 182
Susceptibility weighted MRI can help differentiating pathogenesis of white matter lesions in MS and CNS inflammatory vasculopathies. 178
CSF/serum matrix metallopeptidase‐9 ratio discriminates neuro Behçet from multiple sclerosis 174
MRI evaluation of the "central vein sign" in brain white matter lesions of multiple sclerosis and systemic autoimmune diseases. 174
The diagnosis of multiple sclerosis with markers of "better explanation": accuracy of the "central vein sign" in uncovering pathogenic mechansms different from inflammatory demyelination 173
Differentiation by MRI between multiple sclerosis and MS-like syndromes with markers of "better explanation" of the diagnosis. 172
Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis 172
A case of recurrent progressive multifocal leukoencephalopathy after human stem cell transplant, with detection of John Cunningham virus and human herpesvirus 6 on cerebrospinal fluid, treated with Mirtazapine, Olanzapine and Foscarnet 172
Intermediate-Intensity Autologous Hematopoietic Stem Cell Transplantation Reduces Serum Neurofilament Light Chains and Brain Atrophy in Aggressive Multiple Sclerosis. 172
Leptomeningeal enhancement in multiple sclerosis: a focus on patients treated with hematopoietic stem cell transplantation 171
Severe disease reactivation in two multiple sclerosis patients after natalizumab withdrawal was not halted by monthly administrations of cyclophosphamide - two case reports 171
Association of celiac disease in patients with multiple sclerosis in Tuscany 170
Anti-SARS-Cov2 vaccination at the time of the COVID-19 pandemic: suspected adverse events reporting is the milestone of post-marketing surveillance 170
Investigating Serum sHLA-G Cooperation With MRI Activity and Disease-Modifying Treatment Outcome in Relapsing-Remitting Multiple Sclerosis 166
Case report: A multiple sclerosis patient with imaging features of glymphatic failure benefitted from CSF flow shunting 164
Efficacy of Azathioprine on Multiple Sclerosis new brain lesions evaluated by Magnetic Resonance Imaging. 164
Efficacy of autologous hematopoietic stem cell transplantation in secondary progressive Multiple sclerosis 164
MS patients with low central vein sign frequency can be identified by FLAIR* MRi sequences 163
Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis 163
Autologous hematopoietic stem cell transplantation versus low-dose immunosuppression in secondary-progressive multiple sclerosis 161
Evaluation of dimethyl fumarate efficacy and safety in patients with relapsing remitting multiple sclerosis switching from other treatments 160
Imaging perivenular distribution can differentiate MS from CNS vasculitis. 158
Reconstitution of natural or vaccination-driven immunity after aHSCT in multiple sclerosis 158
Leptomeningeal enhancement analysis in diagnostic clinical setting 157
Modulating dendritic cells (DC) from immunogenic to tolerogenic responses: a novel mechanism of AZA/6-MP. 155
Sustained disease remission in multiple sclerosis after autologous haematopoietic stem cell transplantation. The Italian experience 152
Comparative long term efficacy of beta interferons and azathioprine in relapsing-remitting Multiple sclerosis: single center retrospective 25 year evaluation 150
Disappearance of motor tics after Wernicke's encephalopathy in a patient with Tourette's syndrome 149
CMV AND EBV REACTIVATION AFTER AUTOLOGOUS HAEMOPOIETIC STEM CELL TRANSPLANTATION WITH BEAM CONDITIONING REGIMEN FOR MULTIPLE SCLEROSIS AND LYMPHOMA: A RETROSPECTIVE SINGLE CENTER CASE-CONTROL STUDY 146
Incidence of malignant neoplasms and mortality in people affected by multiple sclerosis in the epoch of disease-modifying treatments: a population-based study on Tuscan residents 146
MMP9 index as possible diagnostic marker of Neuro-Behcet's disease 144
Absence of association between intronic polymorphism in PS-1 gene and alzheimer's disease in italian patients 144
Cerebral perfusion abnormalities in multiple sclerosis patients with markers of systemic autoimmunity 143
Long term follow-up of autologous stem cell transplantation (HSCT) for the treatment of secondary progressive multiple sclerosis: single centre experience 143
Sustained disease remission after discontinuation of disease modifying treatments in relapsing-remitting multiple sclerosis. 142
CNS inflammation during relapsing remitting multiple sclerosis (RRMS): a molecular and cellular analysis of ex vivo CSF T lymphocyte expansions 141
Real Life comparative evaluation of dimethyl fumarate efficacy and tolerability in relapsing remitting multiple sclerosis patients switching from other treatments 141
Comparison of azathioprine and of beta interferon efficacy on measures of brain damage evaluated by MRI in relapsing-remitting multiple sclerosis 140
CMV and EBV reactivation in autologous haemopoietic stem cell transplantation for severe multiple sclerosis 140
Impact of autologous haematopoietic stem cell transplantation on fertility in aggressive multiple sclerosis 139
Azathioprine versus interferon-beta-1a s.c.: efficacy on prevention of new brain lesions in relapsing-remitting multiple sclerosis 139
The Central Vein Sign identifies patients diagnosed with multiple sclerosis probably carrying different diseases and showing milder disease course 139
Mesenchymal Stem Cells and Autoimmune Diseases: The Case of Multiple Sclerosis 138
Management of viral reactivation in multiple sclerosis patients after autologous transplantation with BEAM/ATG conditioning regimen 137
Antigen Driven T-Cell Response in CSF of Multiple Sclerosis Patients 136
Brain atrophy evaluation in multiple sclerosis: change over time of corpus callosum area is more sensitive and reproducible than whole brain volume 135
Direct comparison of Azathioprine and Interferon beta 1a efficacy on prevention of new brain lesions in relapsing-remitting multiple sclerosis 135
Azathioprine-interferon beta 1a s.c. association in relapsing-remitting multiple sclerosis: compliance and efficacy in prevention of new brain lesions 134
Prevalence of disability improvement as a potential outcome for multiple sclerosis trials 134
HSCT for severe multiple sclerosis with BEAM/ATG: impact on female fertility 132
Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis 129
Soluble factor profile in Natalizumab treated MS patients: increased Th1 promoting factors and sHLAg 122
Azathioprine and interferon beta1a relative efficacy on prevention of new brain lesions in relapsing remitting multiple sclerosis 122
intermediate intensity regimen in autologous HSCT for severe Multiple Sclerosis: a a large, single center experience 121
Intermediate intensity regimen in autologous HSCT for severe multiple sclerosis: a large, single center experience 120
Purely myeloablative conditioning regimen in aggressive multiple sclerosis: two case reports 119
Cyclophosphamide pulses therapy after natalizumab discontinuation in Multiple Sclerosis patients 118
Impact of new DMAs on the safety profile of patients undergoing autologous haematopoietic stem cell transplantation for Multiple Sclerosis 115
Safety profile of autologous haematopoietic stem cell transplantation following natalizumab therapy in aggressive forms of multiple sclerosis 113
Thymic hyperplasia after autologous hematopoietic stem cell transplantation in multiple sclerosis: a case series 102
Identification of single nucleotide variations in the coding and regulatory regions of the myelin-associated glycoprotein gene (MAG) and study of their association with multiple sclerosis. 98
Autologous haematopoietic stem cell transplantation affects long-term progression independent of relapse activity in aggressive multiple sclerosis: a comparative matched study 66
EBV Dysregulation Is Associated With Immune Imbalance in Multiple Sclerosis: Evidence From Integrated Viral and Host Analyses 16
Totale 13.348
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.452
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.452
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022444 7 46 23 33 14 13 13 47 22 15 72 139
2022/20231.424 104 268 99 53 95 247 193 83 194 3 47 38
2023/2024750 23 94 84 53 67 82 36 135 18 42 74 42
2024/20254.299 190 435 276 689 1.075 674 64 264 177 79 170 206
2025/20264.613 566 597 352 424 543 165 533 167 296 271 148 551
2026/2027136 136 0 0 0 0 0 0 0 0 0 0 0
Totale 13.348